Replimune REPL
NASDAQ REPL
$15.00 -0.29 (-1.90%)
As of: Sep 4, 2026 · 2:26 PM EDT

Replimune (REPL) Other Operating Expenses (2021 - 2026)

Replimune (REPL) posted Other Operating Expenses of -$1.4 million for Q3 2022, up 0.63% sequentially from -$1.4 million in Q2 2022, and little changed YoY from -$1.4 million in Q3 2021.

Analysis

Replimune (REPL) Other Operating Expenses (2021 - 2026) Analysis & Trends

Replimune has reported Other Operating Expenses for 2 years, with the latest figure at -$1.4 million in Q3 2022.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.87 Bn 131.01 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.57 Bn 77.57 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.19 Bn 53.05 Bn 52.00 Mn
5 Revolution Medicines 44.07 Bn 44.07 Bn -
6 BeOne Medicines 39.99 Bn 34.89 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.38 Bn 32.07 Bn 992.69 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn -
9 Insmed 27.41 Bn 26.25 Bn 358.27 Mn
10 Replimune 1.45 Bn 1.45 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1.40 Mn
Sep 30, 2025 -1.42 Mn
Jun 30, 2025 -1.42 Mn
Sep 30, 2024 -1.42 Mn
Jun 30, 2024 -1.42 Mn
Dec 31, 2022 -1.41 Mn
Sep 30, 2022 -1.41 Mn
Jun 30, 2022 -1.42 Mn
Mar 31, 2022 -1.43 Mn
Dec 31, 2021 -1.41 Mn
Sep 30, 2021 -1.41 Mn
Jun 30, 2021 -1.41 Mn